Our results reveal the immunomodulatory mechanism of low-dose decitabine in ITP by inhibiting CTLs cytotoxicity to autologous platelets through PD-1 pathway. The gene discussed is PDCD1; the disease is autoimmune thrombocytopenic purpura.